CL2023002843A1 - Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente - Google Patents

Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente

Info

Publication number
CL2023002843A1
CL2023002843A1 CL2023002843A CL2023002843A CL2023002843A1 CL 2023002843 A1 CL2023002843 A1 CL 2023002843A1 CL 2023002843 A CL2023002843 A CL 2023002843A CL 2023002843 A CL2023002843 A CL 2023002843A CL 2023002843 A1 CL2023002843 A1 CL 2023002843A1
Authority
CL
Chile
Prior art keywords
antigen
binding fragment
specifically binds
monoclonal antibody
methods
Prior art date
Application number
CL2023002843A
Other languages
English (en)
Spanish (es)
Inventor
Valentinovich MOROZOV Dmitry
Andreevich Ageev Sergei
Sergeevna Chernykh Yulia
Aleksandrovna KONDINSKAIA Diana
Evgenevna Shigina Valeriia
Khaidarovna Sakharova Dina
Anatolevna Grefenshtein Mariia
Konstantinovna Stolyarova Alina
Vladimirovich Solovyev Valery
Andreevich IAKOVLEV Pavel
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021107773A external-priority patent/RU2796937C2/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of CL2023002843A1 publication Critical patent/CL2023002843A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2023002843A 2021-03-24 2023-09-25 Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente CL2023002843A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2021107773A RU2796937C2 (ru) 2021-03-24 Моноклональное антитело или его антигенсвязывающий фрагмент, которое специфически связывается с gd2 (ганглиозид gd2), и его применение

Publications (1)

Publication Number Publication Date
CL2023002843A1 true CL2023002843A1 (es) 2024-03-22

Family

ID=83395963

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023002843A CL2023002843A1 (es) 2021-03-24 2023-09-25 Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente

Country Status (9)

Country Link
CN (1) CN117677695A (zh)
AR (1) AR125219A1 (zh)
CL (1) CL2023002843A1 (zh)
CO (1) CO2023012549A2 (zh)
CR (1) CR20230456A (zh)
EC (1) ECSP23072412A (zh)
TW (1) TW202304989A (zh)
UY (1) UY39687A (zh)
WO (1) WO2022203552A1 (zh)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070967A2 (en) * 2004-01-22 2005-08-04 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
US9315585B2 (en) * 2010-06-19 2016-04-19 Memorial Sloan Kettering Cancer Center Anti-GD2 antibodies
KR102207859B1 (ko) * 2013-03-15 2021-01-27 메모리얼 슬로안 케터링 캔서 센터 고 친화도 항-gd2 항체

Also Published As

Publication number Publication date
ECSP23072412A (es) 2023-10-31
CR20230456A (es) 2023-12-13
CN117677695A (zh) 2024-03-08
TW202304989A (zh) 2023-02-01
UY39687A (es) 2022-08-31
AR125219A1 (es) 2023-06-28
WO2022203552A1 (en) 2022-09-29
CO2023012549A2 (es) 2023-10-09

Similar Documents

Publication Publication Date Title
BR112019008010A2 (pt) anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
PE20211284A1 (es) Anticuerpos anti-nkg2a y usos de los mismos
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
CL2023002690A1 (es) Anticuerpos anti-muc16-cd3 biespecíficos y conjugados anti-muc16-fármacos (divisional de 202102645)
MX2020003888A (es) Anticuerpos terapeuticos postraduccionalmente modificados completamente humanos.
PE20190440A1 (es) Anticuerpos a la alfa-sinucleina y usos de los mismos
PE20210342A1 (es) Anticuerpos anti-sirpa y metodos de utilizacion de los mismos
PE20191079A1 (es) Inmunoglobulinas y usos de estas
BR112015018203A2 (pt) Anti-corpos biespecíficos anti-tnf-anti-il-17
PE20180249A1 (es) Anticuerpos neutralizadores anti-ccl20
WO2021227307A8 (zh) 抗cd73抗体及其用途
BR112017027702A2 (pt) anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2)
EA202192907A1 (ru) Моноклональное антитело, которое специфически связывается с gitr
EA201890805A1 (ru) Биспецифические антитела против cd3*cd19
Maleki et al. Large scale generation and characterization of anti-human CD34 monoclonal antibody in ascetic fluid of Balb/c mice
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
PE20230464A1 (es) Union de anticuerpos multiespecificos a bcma
BR112022000628A2 (pt) Anticorpos anti-tigit e aplicação dos mesmos
PE20211792A1 (es) Anticuerpos monoclonales que se unen especificamene a la region beta de la familia trbv-9 del receptor de celulas t humano, y los metodos para su uso
RU2017145662A (ru) Моноклональные антитела и способы их применения
CL2023002843A1 (es) Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente
AR127635A1 (es) ANTICUERPO MONOCLONAL O FRAGMENTO DE UNIÓN A UN ANTÍGENO QUE SE UNE ESPECÍFICAMENTE A LA IL-4Ra, Y USO DEL MISMO
BR112018070452A2 (pt) um inibidor do receptor de hutnfr1, uma preparação farmacêutica compreendendo o referido inibidor, um método de produção do referido inibidor, uso do referido inibidor na fabricação de um produto para tratamento de um indivíduo humano, um ácido nucleico isolado que codifica o referido inibidor, vetor de expressão e células hospedeiras compreendendo o referido ácido nucleico
ECSP23097121A (es) Anticuerpo biespecífico aislado que se une específicamente a CD47 y PD-L1
BR112022020716A2 (pt) Anticorpos anti-tumor associados ao antígeno e usos dos mesmos